| Literature DB >> 32122549 |
Jianbin Wang1, Vitaly Balan2, Francesco Marincola2.
Abstract
Emergency of the CRISPR technology, a new genome editing tool, revolutionized the biomedical research field in the past 6 years. At the same time, recent advances in cancer immunotherapy reinvigorated our hope to cure most if not all cancer patients with further development of various treatment options. A combination of the CRISPR technology with immuno-oncology research will undoubtedly accelerate the development of new cancer therapies. This review will focus on the CRISPR system and its applications in immune-oncology including identification of immune-oncology gene targets, generation of cancer animal models, and enabling better cell design and manufacture for adoptive cellular therapies.Entities:
Keywords: CAR-T; CRISPR; Cancer; Cas9; Immuno-oncology; Immunotherapy; dCas9; sgRNA
Mesh:
Year: 2019 PMID: 32122549 DOI: 10.1016/bs.mie.2019.05.018
Source DB: PubMed Journal: Methods Enzymol ISSN: 0076-6879 Impact factor: 1.600